In the second batch of anti-cancer and rare disease drugs eligible for the value-added tax (VAT) reduction policy announced recently by several government departments, general VAT taxpayers are subject to a 3% VAT for the production, sale, wholesaling and retailing of the relevant drugs starting from October 2020. More